Navigation Links
TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
Date:5/24/2011

MALVERN, Pa., May 24, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced that is has closed a $6 million investment with new investor Nextech Invest Ltd., a Zurich, Switzerland, based oncology focused venture capital fund.  Combined with the $37 million Series C closed during 2010, TetraLogic has raised $43 million in the past year. The company is investing the funds to complete Phase 2a clinical studies with its lead Smac mimetic drug candidate, TL32711.

"With its European base and oncology expertise, Nextech nicely complements and strengthens our group of investors," said John Gill, TetraLogic's president and CEO.  "The new funds, combined with last year's $37 million in Series C financing, provide the necessary capital to complete several Phase 2a studies in solid tumors and initiate clinical studies in hematological cancers in the upcoming months."

"TetraLogic is a great fit for our oncology portfolio," said Matyas Vegh, Nextech Managing Partner.  "We believe in the potential of Smac mimetics to improve cancer therapy, and we look forward to working with TetraLogic's management and investors to build TL32711 into a leading cancer therapeutic."

About TL32711

TL32711 is a small molecule peptidomimetic of Smac (an endogenous regulator of apoptotic cell death) that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy and in combination with other anti-cancer therapies.  TL32711 is nearing completion of a single agent Phase 1 study in solid tumors and lymphomas and a Phase 1b five-arm combination clinical study in solid tumors.  In the clinical studies to date, TL32711 has been well tolerated and exhibited target suppression and anti-tumor activity. Data fro
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TetraLogic Closes $23 Million Second Tranche of Series C Financing
2. Xlumena, Inc. Closes $7M Series B Venture Financing Round
3. CoDa Therapeutics Closes $19 Million Series B Financing Round
4. Benvenue Medical Closes $35.5 Million Series C Financing
5. PixelOptics Closes $45 Million Financing
6. AnaBios Corporation Closes Series A Financing
7. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
8. OncoSec Medical Closes $1.1M Financing
9. Patient Safety Technologies, Inc. Closes $7.1 Million Common Stock Offering
10. BridgePoint Medical Closes $9.1 Million Series C Financing
11. Palatin Technologies, Inc. Closes $23 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Pa. , July 10, 2014 ... Moberg Research,s (Moberg) medical device manufacturing facility. Rep. ... Moberg,s advanced neurological monitors facilitate cutting-edge research in ... Rep. Kennedy and mental health advocate, Garen ... organization dedicated to fostering fundamental changes that will ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical ... today announced it has entered into an agreement with ... operates as EMD Serono in the United ... to collaborate with Merck KGaA,s biopharmaceutical division on the ... an undisclosed target using Ventana,s proprietary diagnostic assays. In ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... today,announced that the United States Food and Drug ... for the treatment of pulmonary,arterial hypertension (PAH). Terguride ... Phase II trial in Europe., "The FDA,s ... PAH,encourages and strengthens our development program by offering ...
... Tigris Pharmaceuticals,Inc. announced today the execution of a ... Cancer Institute (NCI) to,collaborate on clinical and preclinical ... development. AFP-464 is converted to,metabolites which bind covalently ... This is part of a four-year CRADA encompassing ...
Cached Medicine Technology:Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As reported in ... Institute of Standards and Technology), the June 25th, 2014 Supreme ... electronic discovery world. It was also met with ... depending on whether it was seen from an individual privacy ... much is fact, there is now precedent which will require ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Dubai is ... basketball legend is heading to the UAE. The ... champion will be in the UAE from 28-31 October ... in support of diabetes awareness. The event is being ... marketing and event management company based in Dubai. The ...
(Date:7/12/2014)... 12, 2014 Praeclarus Press ... as a valuable new resource for women in need ... American women work away from their children. Today’s mothers ... benefits of breastfeeding, but often feel unsupported when it ... babies. With its evidence-based insights, and written by Nancy ...
(Date:7/12/2014)... July 12, 2014 Restore My Vision ... and Samantha Pearson, a couple boasting very impressive credentials ... Restore My Vision Today as a way to help ... have become in their respective patients’ treatments . ... to a “secret” trove of pertinent information relevant to ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... Antibiotic resistance is one of the biggest problems worldwide. ... be developed to fight these new antibiotic resistant infections. ... at Colney in Norfolk say they have used natural ... infections. Researchers said the discovery would allow scientists race ...
... used for treating obstructive sleep apnea patients, by making them ... resolving heart abnormalities, says Belgium physicians. // ,OSA ... ,"Not only are the shape and size ... was dilated and the heart muscle on the left side ...
... has been long regarded to be a chronic and unremitting ... temporary or short-lived condition // from which affected individuals can ... the same thing about alcohol. But now I think that ... what compulsive gambling is - for some people it is ...
... the NHS Heath Scotland, has had its lines choked with ... in Scotland since Sunday, last. // The line which ... fold increase of almost 450 calls a day, post ban ... flow of calls. This is a shot in the arm ...
... of the European Commission would be targeted towards controlling ... and malaria // that are haunting the Asian region. ... and TB through External Action' would be launched neat ... aimed at reducing the financial constraints that prevent the ...
... syndrome (PTSD) is a disabiling anxiety disorder, which was ... World War I, as soldier's heart and shell shock ... who are affected by cancer and their families as ... PTSD affects about 10 percent of those exposed to ...
Cached Medicine News:Health News:Compulsive Gambling Not A Chronic Addiction Always: Research 2Health News:Control And Prevention Of Three Diseases To Be Discussed: European Commission 2Health News:New Therapy For Treating Post-Traumatic Stress Syndrome 2
... to over 2,000 medical clinics nation wide, ... in mind, ChartingPlus relies heavily on a ... to improve documentation quality and increase productivity ... medical content is specific to your medical ...
... EncounterPRO Electronic Health Record ... System (WfMS) Specialties that ... and Immunology, Cardiology, Dermatology, ... Medicine, Neurology, Neurosurgery, Obstetrics ...
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
... Medical Record Software Interface ... Interface with programs, populates ... custom reports. Accumedics Electronic ... is Microsoft compatible allowing ...
Medicine Products: